News & Updates

New drug applications approved by US FDA as of 16-28 February 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Nightly use of 0.05% atropine eye drops among children appears to lead to a significantly lower incidence of near-sightedness, as shown in the results of the LAMP2 study from Hong Kong.

Treatment with repeated low-level red-light (RLRL) therapy with 100-percent power results in significant reduction in myopia progression over 6 months in myopic children when compared to a sham device with 10-percent original power, a China study has shown. In addition, the RLRL therapy is well tolerated and does not lead to serious adverse effects (AEs)

The term ‘papilledema’ is often used inappropriately among case reports in ophthalmology, reveals a recent study. Such misuse, if not corrected, can result in improper care delivery to patients with optic disc edema (ODE), which may then lead to permanent vision loss.

Use of proprotein convertase subtilisin-like/kexin type 9 (PCSK9) inhibitors appears to increase the risk of ocular disorders, as shown in a study.